Opening the book…
Postmarket surveillance looks for safety problems that may not have appeared in trials. Sources include reports from patients and health professionals, required
manufacturer reports, research studies, and other surveillance systems. A report does not by itself prove causation. Findings may lead to labeling changes, further studies, risk controls, recalls, or withdrawal of approval when warranted.
A new indication usually requires additional supporting evidence and an appropriate supplemental application before the company may market the drug for that use. Existing evidence may help, but its relevance depends on factors such as dose, route, population, and treatment duration.
After approval, a report of a problem is a signal to evaluate, not automatic proof that the product caused the event. The company may need information about the product, lot, dose, storage, other medicines, timing, and the person’s condition. Missing details can make interpretation difficult, so accurate intake and follow-up processes matter.
Safety monitoring and quality investigations can overlap. For example, several complaints about unusual particles may prompt a review of retained samples, manufacturing records, packaging components, and distribution information. A reported symptom may also require safety evaluation. Different specialists contribute, and communication helps prevent a concern from being lost between departments.
Quality trends can reveal a developing problem before one result clearly fails. Increasing complaints about leaking containers, for example, may justify closer examination even if individual laboratory results remain acceptable. The response should be based on the pattern, product risks, and available evidence rather than waiting for confirmed harm. This example is hypothetical.
Tracing an Affected Batch
Traceability is the ability to follow materials and products through manufacturing and distribution records. A recall investigation uses these records to identify affected lots and determine where they went. Useful identifiers include strength, dosage form, lot number, package size, and expiration date.
Consider a hypothetical investigation that links a closure defect to containers used in three batches. The team must determine where those batches went and whether other products used the same closures. Manufacturing, purchasing, laboratory, warehouse, distribution, and quality personnel may all hold part of the evidence.
Communication must tell the intended audience how to recognize the affected product and what action to take. Staff also need to track the response and reconcile available information about distributed and recovered units. Retrieving product addresses the immediate concern, while investigation and corrective action address the conditions that allowed it to occur.
A recall can protect people while creating difficult practical consequences. Patients and caregivers may need clear information, and health professionals may need to help identify alternatives. These human effects show why prevention, timely investigation, and accurate records matter long before a recall is considered.
Most drug recalls are voluntary, initiated by a company or requested by FDA. FDA lacks broad mandatory recall authority for most drugs, but it has specific authority for certain controlled substances when statutory serious-risk criteria are met. Other product categories have their own authorities. Therefore, the statement that FDA can never order a drug recall is too broad.
The existence and scope of mandatory recall authority depend on the product and legal provision. Do not assume that a food or device authority applies to all medicines.
Recall Classes
Class I recall — There is a reasonable probability that use of, or exposure to, the product will cause serious adverse health consequences or death.
Class II recall — Use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences, or the probability of serious adverse health consequences is remote.
Class III recall — Use of, or exposure to, the product is not likely to cause adverse health consequences.
Market withdrawal — A company removes or corrects a marketed product for a minor violation that would not be subject to FDA legal action, or for a reason involving no violation. A withdrawal is distinct from a recall. A tampering incident must be assessed on its facts; the term does not automatically apply to every tampering event.
This page titled 12.6: Postmarket Monitoring and Recall Decisions was last modified on Sun, 08 Nov 2026 14:39:38 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.
The book could not be loaded just now.